Establishment Labs (ESTA) Q4 2025 earnings review
Textbook Operating Leverage: U.S. Launch Catapults ESTA to Profitability
Establishment Labs delivered a flawless quarter. The U.S. Motiva launch drove a massive 45.2% YoY revenue surge, but the real story is on the bottom line. SG&A stayed completely flat YoY at $44.0 million while revenue jumped $20 million, driving Adjusted EBITDA to a record $5.5M. The cash burn narrative is officially dead—cash increased by $4.9M sequentially. With 2026 guidance forecasting 25%+ growth and positive cash flow, ESTA is rapidly seizing market share from legacy incumbents while self-funding its expansion.
🐂 Bull Case
The U.S. Motiva launch is a runaway success. FY25 U.S. revenue hit $45.6M, comfortably beating the company's heavily raised guidance. Q4 alone generated $17.3M, proving rapid surgeon onboarding and deep patient pull-through.
For the first time, ESTA generated positive cash flow in a quarter (cash balance rose $4.9M QoQ to $75.6M). The company is now fully funded to execute its 2026 growth plans without dilutive equity raises.
🐻 Bear Case
Management is boldly guiding for 25%+ topline growth in both 2026 and 2027. Any macroeconomic softening in consumer aesthetic spending or FDA delays for product line extensions could severely punish the stock.
While the U.S. is surging, international markets—specifically China—have faced severe consumer macro headwinds and distributor inventory gluts, forcing the company to remove China from H2 2025 guidance entirely.
⚖️ Verdict: 🟢🟢
Strongly Bullish. ESTA is executing a rare feat in MedTech: hyper-growth (>45%) paired with absolute cost discipline (0% SG&A growth). The transition to positive cash flow derisks the balance sheet entirely.
Key Themes
Textbook Operating Leverage Realized
The most impressive data point in the Q4 print is SG&A expense: exactly $44.0M in Q4 2025, perfectly flat compared to $44.0M in Q4 2024. During this exact same timeframe, revenue grew by $20.1M (+45%). This extreme cost discipline proves management's earlier claims that investments made ahead of the U.S. launch are now scaling efficiently. This is the primary driver of the $18.6M YoY swing in Adjusted EBITDA.
U.S. Motiva Sequential Acceleration
The U.S. growth engine is accelerating rapidly. Sequential U.S. revenue growth: Q1 ($6.2M) -> Q2 ($10.3M) -> Q3 ($11.9M) -> Q4 ($17.3M). The company is successfully transitioning from onboarding new accounts to driving deep utilization within converted clinics. The brand is experiencing unprecedented consumer pull-through, with patients specifically asking for Motiva by name.
Minimally Invasive Platform Premiumization
Preservé and Mia Femtech are establishing a new, premium-priced category in breast aesthetics. Early data from the Preservé U.S. rollout indicates the ability to command up to a 40% price premium over legacy procedures. This not only drives top-line expansion but acts as a structural gross margin enhancer.
China Macro Weakness Contradicts Global narrative
While the U.S. prints massive beats, the global macro picture is mixed. ESTA was forced to pull China from its H2 2025 guidance due to a weak consumer environment and distributor inventory issues. Total Q4 Revenue was $64.6M; backing out $17.3M from the U.S. leaves $47.3M for the Rest of World. While growing, the OUS segment is decelerating relative to the company average, making ESTA highly reliant on continuous flawless U.S. execution.
Incumbent Retaliation Risks
Management stated they aim to exit 2025 with ~20% U.S. market share and have long-term goals of 40-70%. Legacy competitors (Allergan, Mentor) will not surrender this highly profitable market without a fight. While ESTA has only seen 'localized price discounting' so far, a coordinated, aggressive pricing war from incumbents remains a persistent tail risk.
Gross Margin Stabilization
Gross margins hit 70.5% in Q4, up from 68.5% a year ago. This expansion is strictly driven by geographic mix shift—U.S. average selling prices are significantly higher than international markets. As U.S. sales become a larger portion of total revenue, we expect gross margins to structurally settle in the low 70s.
Other KPIs
Accelerating. Up 200 bps from 68.5% in 24Q4. The geographic mix shift toward the higher-priced U.S. market continues to pull up the corporate average, heavily offsetting any potential supply chain or tariff-related cost pressures.
Reversing. For the first time, cash flow turned definitively positive. The balance increased by $4.9M sequentially from Q3, effectively ending concerns regarding the need for near-term equity dilution. The company also carries a $247.5M long-term note from Oaktree, but operating cash flow is now covering debt service and expansion needs.
Guidance
Accelerating. Implies 25.1% to 26.0% YoY growth. This is a highly confident guide given the law of large numbers; maintaining a 25%+ growth rate on a base that just grew 27% requires the U.S. Motiva adoption curve to continue steepening without major incumbent disruption.
Stable. Projecting out two years with a >25% growth floor signals management's absolute confidence in pipeline rollouts, specifically the full commercialization of Preservé and pending FDA approvals for breast reconstruction indications.
Key Questions
International Normalization
With China pulled from the H2 2025 guidance due to distributor inventory gluts, what is the timeline for destocking, and should we expect a resumption of normalized APAC order flow in H1 2026?
U.S. Penetration Depth
You exited 2025 with massive U.S. momentum. What percentage of your 1,000+ U.S. clinics are now utilizing Motiva for more than 50% of their total augmentations, and where is the ceiling on share-of-wallet per clinic?
Reconstruction Indication Timeline
With the aesthetic market share grab performing well, what is the exact status and expected timeline for the FDA PMA supplement for U.S. breast reconstruction, which opens up a massive adjacent TAM?